Nuclea, Thermo Fisher Collaborating on Mass Spec Assays for Type 2 Diabetes
Nuclea Biotechnologies and Thermo Fisher Scientific said today that they are collaborating on multiplexed mass spec assays for quantifying native insulin and its therapeutic analogs.
Nuclea plans to use the assays to analyze patient samples as part of the company's diabetes research collaborations.
The assays will be developed at Thermo Fisher's Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center and will be run using Thermo Fisher's MSIA immunoenrichment technology and its TSQ Vantage or Quantiva mass spec instruments.
"We’ve already worked with the BRIMS Center to develop two other very important assays," Nuclea CEO Patrick Muraca said in a statement. "These assays have demonstrated the sensitivity, precision, and robustness needed for high-throughput detection of clinically relevant isoforms of target proteins."
"The real-world application of multiplexed MS-based methods to type 2 diabetes presents an opportunity to advance research in this crucial area," said BRIMS Center Director Mary Lopez. "Nuclea’s proven ability to validate and develop routine assays means our collaboration can support research efforts."
Financial and other terms of the agreement were not disclosed.
Nuclea plans to use the assays to analyze patient samples as part of the company's diabetes research collaborations.
The assays will be developed at Thermo Fisher's Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center and will be run using Thermo Fisher's MSIA immunoenrichment technology and its TSQ Vantage or Quantiva mass spec instruments.
"We’ve already worked with the BRIMS Center to develop two other very important assays," Nuclea CEO Patrick Muraca said in a statement. "These assays have demonstrated the sensitivity, precision, and robustness needed for high-throughput detection of clinically relevant isoforms of target proteins."
"The real-world application of multiplexed MS-based methods to type 2 diabetes presents an opportunity to advance research in this crucial area," said BRIMS Center Director Mary Lopez. "Nuclea’s proven ability to validate and develop routine assays means our collaboration can support research efforts."
Financial and other terms of the agreement were not disclosed.
Comments